Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $135.18, with a high estimate of $155.00 and a low estimate of $110.00. Highlighting a 3.58% ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

CureVac (CVAC) stock jumps as BioNTech (BNTX) agrees to acquire in an all-stock deal worth $1.25B. Read more here.

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality. According to the deal, ...

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialized in mRNA technology with the goal of advancing ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.

CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine development to its alliance partner, Britain's GSK ...